Our Successes
For over 30 years, PharmaVentures has acted as advisor on over 1,000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
Here we show a few project examples to illustrate the PharmaVentures expertise.

PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM

PharmaVentures advises Novartis on the sale of its manufacturing facility in Barberà del Vallès to Siegfried Holding AG

PharmaVentures advises Vital Foods on the sale of its Zyactinase-based digestive health product asset portfolio to Mundipharma

PharmaVentures Capital Limited advises Biosceptre International Limited, a clinical stage oncology company, on its Series A private placement by Tuspark S&T

PharmaVentures advises IDT Australia on the divestment of CMAX clinical trial business to the Japanese company I’rom Group Co. Ltd.

PharmaVentures advises the Baylor Scott & White Research Institute on collaboration with Abzena plc and creation of Denceptor Therapeutics

PharmaVentures advises 3Legs Resources on its acquisition of the Immuno-Oncology company SalvaRx who announced its admission for trading on AIM today

PharmaVentures’ Latest Deal: Douglas Pharmaceuticals acquires Vital Foods’ Phloe product line in New Zealand

PharmaVentures Advises ESTEVE in Its pharma licensing Deal for E-58425, a New Therapeutic Product for Pain

PharmaVentures Advises MedGenesis in Agreement with Pfizer for Its Potential Therapy for Parkinson’s Disease

PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva’s Hlovovec Production Facility to Wood Pharma Holding









